Luke Fischer, MD, PhD

Title(s)CLINICAL FELLOW, Neurology
SchoolSchool of Medicine
Address675 Nelson Rising Lane
San Francisco CA 94158
Phone--
ORCID ORCID Icon0000-0002-5245-3832 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of Alabama at Birmingham, Birmingham, ALResident06/2022Neurology
    Michigan State University, Grand Rapids, MIMD05/2018
    Michigan State University, Grand Rapids, MIPostdoc06/2016Neuroscience
    Michigan State University, Grand Rapids, MIPhD06/2015Neuroscience
    Michigan State University, East Lansing, MIBS05/2010Biochemistry & Molecular Biology
    Michigan State University, East Lansing, MIBA05/2010Philosophy

    Collapse Overview 
    Collapse Overview
    D. Luke Fischer is a neurologist-neuroscientist with an interest in cognition in neuronal synucleinopathies. He graduated Phi Beta Kappa from Michigan State University with degrees in Philosophy and Biochemistry & Molecular Biology, and he remained there to complete his PhD degree in Neuroscience in the laboratory of Dr. Caryl E. Sortwell as part of a dual-MD/PhD program. As a trainee in the NINDS Morris K. Udall Center of Excellence for Parkinson's Disease Research at Michigan State University, his focus was on the use of deep brain stimulation in rodent models of Parkinson's disease to investigate its potential as a neuroprotective therapy. He remained in her laboratory as a postdoctoral fellow to examine the impact of common genetic variants on clinical outcomes for developing precision medicine approaches for treating patients with Parkinson's disease. He completed his neurology residency at the University of Alabama at Birmingham where he was elected to AOA and served as Chief Resident. As a NINDS R25 resident trainee in the laboratory of Dr. Laura Volpicelli-Daley, he applied confocal and expansion microscopy techniques to human postmortem brain samples to examine co-pathology. Luke is currently a Fellow in the Behavioral Neurology Training Program at the University of California San Francisco.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. BDNF rs6265 Genotype Influences Outcomes of Pharmacotherapy and Subthalamic Nucleus Deep Brain Stimulation in Early-Stage Parkinson's Disease. Neuromodulation. 2022 Aug; 25(6):846-853. Sortwell CE, Hacker ML, Fischer DL, Konrad PE, Davis TL, Neimat JS, Wang L, Song Y, Mattingly ZR, Cole-Strauss A, Lipton JW, Charles PD. PMID: 34288271; PMCID: PMC8770717.
      View in: PubMed   Mentions: 1     Fields:    
    2. BDNF rs6265 Variant Alters Outcomes with Levodopa in Early-Stage Parkinson's Disease. Neurotherapeutics. 2020 10; 17(4):1785-1795. Fischer DL, Auinger P, Goudreau JL, Cole-Strauss A, Kieburtz K, Elm JJ, Hacker ML, Charles PD, Lipton JW, Pickut BA, Sortwell CE. PMID: 33215284; PMCID: PMC7851242.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    3. The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in rats. Neurobiol Dis. 2021 01; 148:105175. Mercado NM, Stancati JA, Sortwell CE, Mueller RL, Boezwinkle SA, Duffy MF, Fischer DL, Sandoval IM, Manfredsson FP, Collier TJ, Steece-Collier K. PMID: 33188920; PMCID: PMC7855552.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    4. External Ventricular Drain Placement Accuracy and Safety When Done by Midlevel Practitioners. Neurosurgery. 2019 01 01; 84(1):235-241. Ellens NR, Fischer DL, Meldau JE, Schroeder BA, Patra SE. PMID: 29618119.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    5. BDNF provides many routes toward STN DBS-mediated disease modification. Mov Disord. 2019 01; 34(1):22-34. Fischer DL, Sortwell CE. PMID: 30440081; PMCID: PMC6587505.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    6. Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson's Disease. Front Neurosci. 2018; 12:621. Duffy MF, Collier TJ, Patterson JR, Kemp CJ, Fischer DL, Stoll AC, Sortwell CE. PMID: 30233303; PMCID: PMC6132025.
      View in: PubMed   Mentions: 16  
    7. Correction to: Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration. J Neuroinflammation. 2018 May 29; 15(1):169. Duffy MF, Collier TJ, Patterson JR, Kemp CJ, Luk KC, Tansey MG, Paumier KL, Kanaan NM, Fischer DL, Polinski NK, Barth OL, Howe JW, Vaikath NN, Majbour NK, El-Agnaf OMA, Sortwell CE. PMID: 29843738; PMCID: PMC5975483.
      View in: PubMed   Mentions: 3     Fields:    
    8. Bdnf variant is associated with milder motor symptom severity in early-stage Parkinson's disease. Parkinsonism Relat Disord. 2018 08; 53:70-75. Fischer DL, Auinger P, Goudreau JL, Paumier KL, Cole-Strauss A, Kemp CJ, Lipton JW, Sortwell CE. PMID: 29759928.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    9. Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration. J Neuroinflammation. 2018 May 01; 15(1):129. Duffy MF, Collier TJ, Patterson JR, Kemp CJ, Luk KC, Tansey MG, Paumier KL, Kanaan NM, Fischer DL, Polinski NK, Barth OL, Howe JW, Vaikath NN, Majbour NK, El-Agnaf OMA, Sortwell CE. PMID: 29716614; PMCID: PMC5930695.
      View in: PubMed   Mentions: 61     Fields:    Translation:AnimalsCells
    10. Subthalamic Nucleus Deep Brain Stimulation Does Not Modify the Functional Deficits or Axonopathy Induced by Nigrostriatal α-Synuclein Overexpression. Sci Rep. 2017 11 27; 7(1):16356. Fischer DL, Manfredsson FP, Kemp CJ, Cole-Strauss A, Lipton JW, Duffy MF, Polinski NK, Steece-Collier K, Collier TJ, Gombash SE, Buhlinger DJ, Sortwell CE. PMID: 29180681; PMCID: PMC5703955.
      View in: PubMed   Mentions: 6     Fields:    Translation:AnimalsCells
    11. Can STN DBS protect both nigral somata and innervation of the striatum? Ann Neurol. 2017 11; 82(5):855. Fischer DL, Manfredsson FP, Sortwell CE. PMID: 28985650.
      View in: PubMed   Mentions: 1     Fields:    Translation:Animals
    12. Subthalamic Nucleus Deep Brain Stimulation Employs trkB Signaling for Neuroprotection and Functional Restoration. J Neurosci. 2017 07 12; 37(28):6786-6796. Fischer DL, Kemp CJ, Cole-Strauss A, Polinski NK, Paumier KL, Lipton JW, Steece-Collier K, Collier TJ, Buhlinger DJ, Sortwell CE. PMID: 28607168; PMCID: PMC5508259.
      View in: PubMed   Mentions: 18     Fields:    Translation:AnimalsCells
    13. Alpha-Synuclein mRNA Is Not Increased in Sporadic PD and Alpha-Synuclein Accumulation Does Not Block GDNF Signaling in Parkinson's Disease and Disease Models. Mol Ther. 2017 10 04; 25(10):2231-2235. Su X, Fischer DL, Li X, Bankiewicz K, Sortwell CE, Federoff HJ. PMID: 28522034; PMCID: PMC5628770.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    14. Impact of age and vector construct on striatal and nigral transgene expression. Mol Ther Methods Clin Dev. 2016; 3:16082. Polinski NK, Manfredsson FP, Benskey MJ, Fischer DL, Kemp CJ, Steece-Collier K, Sandoval IM, Paumier KL, Sortwell CE. PMID: 27933309; PMCID: PMC5142515.
      View in: PubMed   Mentions: 12  
    15. Viral Vector-Based Modeling of Neurodegenerative Disorders: Parkinson's Disease. Methods Mol Biol. 2016; 1382:367-82. Fischer DL, Gombash SE, Kemp CJ, Manfredsson FP, Polinski NK, Duffy MF, Sortwell CE. PMID: 26611600.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCells
    16. High-Frequency Stimulation of the Rat Entopeduncular Nucleus Does Not Provide Functional or Morphological Neuroprotection from 6-Hydroxydopamine. PLoS One. 2015; 10(7):e0133957. Fischer DL, Collier TJ, Cole-Strauss A, Wohlgenant SL, Lipton JW, Steece-Collier K, Manfredsson FP, Kemp CJ, Sortwell CE. PMID: 26222442; PMCID: PMC4519335.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    17. Neuroprotective potential of pleiotrophin overexpression in the striatonigral pathway compared with overexpression in both the striatonigral and nigrostriatal pathways. Gene Ther. 2014 Jul; 21(7):682-93. Gombash SE, Manfredsson FP, Mandel RJ, Collier TJ, Fischer DL, Kemp CJ, Kuhn NM, Wohlgenant SL, Fleming SM, Sortwell CE. PMID: 24807806; PMCID: PMC4326069.
      View in: PubMed   Mentions: 19     Fields:    Translation:AnimalsCells
    Luke's Networks
    Concepts (85)
    Derived automatically from this person's publications.
    _
    Co-Authors (1)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _